Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumour PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion

British Journal of Cancer

Volumn 73, Issue 5, 1996, Pages 596-602

  Verovski, V N ^a   Van Den Berge, D L ^a   Delvaeye, M M ^a   Scheper, R J ^b   De Neve, W J ^a   Storme, G A ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Brefeldin A; Doxorubicin resistance; Fluoroaluminate; G protein; Genistein; Vesicular transport

Indexed keywords

BREFELDIN A; CELL MARKER; DOXORUBICIN; FLUOROALUMINATE; GENISTEIN; GLYCOPROTEIN P; NOCODAZOLE; VERAPAMIL;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG TRANSPORT; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PANCREAS TUMOR; PRIORITY JOURNAL;

EID: 0030046573     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.103     Document Type: Article

References (30)

1. BARR FA, LEYTE A, MOLLNER S, PFEUFFER T, TOOZE SA AND HUTTNER WB. (1991). Trimeric G-proteins of the trans-Golgi network are involved in the formation of constitutive secretory vesicles and immature secretory granules. FEBS Lett., 294, 239-243.
2. BARRAND MA, RHODES T, CENTER MS AND TWENTYMAN PR. (1993). Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190 K membrane protein distinct from P-glycoprotein. Br. J. Cancer, 29, 408-415.
3. BECK WT. (1987). The cell biology of multiple drug resistance. Biochem. Pharmacol., 36, 2879-2887.
4. BREITFELD PP, MCKINNON WC AND MOSTOV KE. (1990). Effect of nocodazole on vesicular traffic to the apical and basolateral surfaces of polarized MDCK cells. J. Cell Biol., 111, 2365-2373.
5. COLE SPC, BHARDWAJ G, GERLACH JH, MACKIE JE, GRANT CE, ALMQUIST KC, STEWART AJ, KURZ EU, DUNCAN AMV AND DEELEY RG. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, 1650-1654.
6. COLE SPC, SPARKS KE, FRASER K, LOE DW, GRANT CE, WILSON GM AND DEELEY RG. (1994). Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res., 54, 5902-5910.
7. COLEY HM, AMOS WB, TWENTYMAN PR AND WORKMAN P. (1993). Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br. J. Cancer, 67, 1316-1323.
8. DELVAEYE M, VEROVSKI V, DE NEVE W AND STORME G. (1993). DNA breakage, cytotoxicity, drug accumulation and retention in two human ovarian tumor cell lines AZ224 and AZ364 treated with adriamycin, modulated by verapamil. Anticancer Res., 13, 1533-1538.
9. DONALDSON JG, FINAZZI D AND KLAUSNER RD. (1992). Brefeldin A inhibits Golgi membrane-catalysed exchange of guanine nucleotide onto ARF protein. Nature, 360, 350-352.
10. DUAN RD, WAGNER ACC, YULE DI AND WILLIAMS JA. (1994). Multiple inhibitory effects of genistein on stimulus-secretion coupling in rat pancreatic acini. Am. J. Physiol., 266, G303-G310.
11. EIJDEMS EWHM, ZAMAN GJR, DE HAAS M, VERSANTVOORT CHM, FLENS MJ, SCHEPER RJ, KAMST E, BORST P AND BAAS F. (1995). Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells. Br. J. Cancer, 72, 298-306.
12. FLENS MJ, IZQUIERDO MA, SCHEFFER GL, FRITZ JM, MEIJER CJLM, SCHEPER RJ AND ZAMAN GJR. (1994). Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res., 54, 4557-4563.
13. GERVASONI Jr JE, FIELDS SZ, KRISHNA S, BAKER MA, ROSADO M, THURAISAMY K, HINDENBURG AA AND TAUB RN. (1991). Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res., 51, 4955-4963.
14. GOTTESMAN MM AND PASTAN I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427.
15. KLAUSNER RD, DONALDSON JG AND LIPPINCOTT-SCHWARTZ J. (1992). Brefeldin A: insights into the control of membrane traffic and organelle structure. J. Cell Biol., 116, 1071-1080.
16. KTISTAKIS NT, LINDER ME AND ROTH MG. (1992). Action of brefeldin A blocked by activation of a pertussis-toxin-sensitive G protein. Nature, 356, 344-346.
17. MCGRATH T, LATOUD C, ARNOLD ST, SAFA AR, FELSTED RL AND CENTER MS. (1989). Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of MDR gene expression. Biochem. Pharmacol., 38, 3611-3619.
18. MAILLET B, DE GREVE J, LEMOINE N, KALTHOFF H, SCHMIEGEL W AND KLÖPPEL G. (1993). Phenotypical differentiation and genetic alterations in human pancreatic carcinoma cell lines. Int. J. Pancreatol., 14, 72-75.
19. MARQUARDT D AND CENTER MS. (1992). Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells. Cancer Res., 52, 3157-3163.
20. 1, and 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (NBD) of cellular accumulation and intracellular distribution of anthracyclines in the non-P-glycoprotein-mediated multidrug-resistant cell line COR-L23/R. Br. J. Cancer, 70, 60-66.
21. SCHEPER RJ, BULTE JWM, BRAKKEE JGP, QUAK JJ, VAN DER SCHOOT E, BALM AJM, MEIJER CJLM, BROXTERMAN HJ, KUIPER CM, LANKELMA J AND PINEDO HM. (1988). Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int. J. Cancer, 42, 389-394.
22. SCHEPER RJ, BROXTERMAN HJ, SCHEFFER GL, KAAIJK P, DALTON WD, VAN HEIJNINGEN THM, VAN KALKEN CK, SLOVAK ML, DE VRIES EGE, VAN DER VALK P, MEIJER CJLM AND PINEDO HM. (1993). Overexpression of a M, 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res., 53, 1475-1479.
23. SEHESTED M, SKOVSGAARD T, VAN DEURS B AND WINTHERNIELSEN H. (1987). Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil. Br. J. Cancer, 56, 747-751.
24. SUPINO R, BINASCHI M, CAPRANICO G, GAMBETTA RA, PROSPERI E, SALA E AND ZUNINO F. (1993). A study of cross-resistance pattern and expression of molecular markers of multidrug resistance in a human small-cell lung-cancer cell line selected with doxorubicin. Int. J. Cancer, 54, 309-314.
25. TAKEDA Y, NISHIO K, NIITANI H AND SAIJO N. (1994). Reversal of multidrug resistance by tyrosine-kinase inhibitors in a non-P-glycoprotein-mediated multidrug-resistant cell line. Int. J. Cancer, 57, 229-239.
26. TWENTYMAN PR, RHODES T AND RAYNER S. (1994). A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur. J. Cancer, 9, 1360-1369.
27. VEROVSKI V, DELVAEYE M, VAN DEN BERGE D, DE NEVE W AND STORME G. (1994). Reversing potential of brefeldin A in non-P-glycoprotein mediated cellular resistance to adriamycin. 1st International Conference on reversal of multidrug resistance in cancer (abstr.). Anti-Cancer Drugs, 5 (suppl. 1), 31-32.
28. VERSANTVOORT CHM, SCHUURHUIS GJ, PINEDO HM, EEKMAN CA, KUIPER CM, LANKELMA J AND BROXTERMAN HJ. (1993). Genistein modulates the decreased drug accumulation in non-P-glycoprotein-mediated multidrug-resistant tumour cells. Br. J. Cancer, 68, 939-946.
29. VERSANTVOORT CHM, BROXTERMAN HJ, LANKELMA J, FELLER N AND PINEDO HM. (1994). Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem. Pharmacol., 6, 1129-1136.
30. VICHI PJ AND TRITTON TR. (1993). Protection from adriamycin cytotoxicity in L1210 cells by brefeldin A. Cancer Res., 53, 5237-5243.